Jaguar Health Inc (JAGX)

Apr 30, 2025

Jaguar Health (JAGX) Reports Positive Trial Results for Crofelemer Formulation | JAGX Stock News - GuruFocus

Apr 30, 2025

Apr 30, 2025

Jaguar Health Announces Promising Crofelemer Trial Results - TipRanks

Apr 30, 2025

Apr 30, 2025

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5%Potential to Modify Disea - Yahoo Finance

Apr 30, 2025

Apr 29, 2025

REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Pre - GuruFocus

Apr 29, 2025

Apr 29, 2025

Breakthrough Data: New Treatment Hope for Ultra-Rare Pediatric Disease MVIDKey Results Revealed - Stock Titan

Apr 29, 2025

Apr 29, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 29, 2025

Apr 28, 2025

Jaguar Health to Present Initial Results from the Proof-of-Conce - GuruFocus

Apr 28, 2025

Apr 28, 2025

Jaguar Health (JAGX) to Host Webcast on Crofelemer Trials for Ra - GuruFocus

Apr 28, 2025

Apr 28, 2025

Jaguar Health Schedules Webcast on Crofelemer Trial Results - TipRanks

Apr 28, 2025

Apr 28, 2025

Breakthrough Clinical Data: New Treatment Hope for Two Ultra-Rare Intestinal Diseases Shows Early Promise - Stock Titan

Apr 28, 2025

Apr 26, 2025

Jaguar Health's (JAGX) Crofelemer Shows Promise in Breast Cancer Subgroup - GuruFocus

Apr 26, 2025

Apr 25, 2025

Jaguar Health Presents at Elite Ped-GI Congress 2025 - TipRanks

Apr 25, 2025

Apr 25, 2025

Jaguar Health (JAGX) Reports Progress in Rare Disease Drug Trial - GuruFocus

Apr 25, 2025

Apr 17, 2025

Jaguar Health's (JAGX) Crofelemer Trial Shows Promise for Rare Disorders | JAGX Stock News - GuruFocus

Apr 17, 2025

Apr 17, 2025

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress | JAGX Stock News - GuruFocus

Apr 17, 2025

Apr 17, 2025

First-Ever MVID Treatment? Crucial Trial Data for Orphan Drug Crofelemer Coming to Elite Congress - Stock Titan

Apr 17, 2025

Apr 16, 2025

Jaguar Health to present results from OnTarget study in breast cancer patients - Yahoo Finance

Apr 16, 2025

Apr 15, 2025

Jaguar Health to discuss breast cancer treatment with FDA By Investing.com - Investing.com South Africa

Apr 15, 2025

Apr 15, 2025

Jaguar Health (JAGX) Advances OnTarget Study with Key Presentati - GuruFocus

Apr 15, 2025

Apr 15, 2025

Jaguar Health to discuss breast cancer treatment with FDA - Investing.com

Apr 15, 2025

Apr 15, 2025

Jaguar Health Announces Significant Results in Breast Cancer Pat - GuruFocus

Apr 15, 2025

Apr 15, 2025

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting | JAGX Stock News - GuruFocus

Apr 15, 2025

Apr 15, 2025

Game-Changing Results: New Cancer Drug Shows Remarkable Success in Breast Cancer Patients - Stock Titan

Apr 15, 2025

Apr 08, 2025

Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Call Transcript - MSN

Apr 08, 2025

Apr 08, 2025

Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea - ACCESS Newswire

Apr 08, 2025

Apr 08, 2025

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting - GuruFocus

Apr 08, 2025

Apr 08, 2025

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - markets.businessinsider.com

Apr 08, 2025

Apr 08, 2025

Revolutionary Pain Relief: New FDA-Approved Treatment Transforms Cancer Care Experience - Stock Titan

Apr 08, 2025

Apr 06, 2025

Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer - ACCESS Newswire

Apr 06, 2025

Apr 05, 2025

Jaguar Health (NASDAQ:JAGX) Shares Cross Below Two Hundred Day Moving Average – What’s Next? - Defense World

Apr 05, 2025

Apr 04, 2025

Jaguar Animal Health Secures $3.448M in Private Placement - TipRanks

Apr 04, 2025

Apr 04, 2025

Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials - ACCESS Newswire

Apr 04, 2025

Apr 04, 2025

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire

Apr 04, 2025

Apr 04, 2025

Jaguar Health Expands Workforce: New Stock Grants Signal Growth Strategy - Stock Titan

Apr 04, 2025

Apr 03, 2025

Jaguar Health outlines key Q2 2025 catalysts for crofelemer programs - MSN

Apr 03, 2025

Apr 03, 2025

Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product - ACCESS Newswire

Apr 03, 2025

Apr 02, 2025

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - ACCESS Newswire

Apr 02, 2025

Apr 01, 2025

Jaguar Health completes $3.4 million private placement By Investing.com - Investing.com South Africa

Apr 01, 2025